Based on these results, the U.S. Food and Drug Administration (but not the European Medicines Agency) contraindicated treatment with GLP-1 RAs in subjects who had a personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2. Here, GLP1R is linked to medullary thyroid gland carcinoma.